Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978898 | 0.85 | TSHR (0.59) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL4547845 | 0.82 | TSHR (0.55) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL18562545 | 0.82 | TDP1 (0.50) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL28847439 | 0.82 | TDP1 (0.50) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL29947157 | 0.82 | TDP1 (0.50) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL6234170 | 0.79 | PDK1 (0.44) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL12381771 | 0.79 | MAPT (0.53) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL27764339 | 0.78 | MAPT (0.48) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL9501203 | 0.78 | TSHR (0.58) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL30811540 | 0.78 | TSHR (0.58) | TDP1TSHRMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543863-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | University Of Ottawa (CA) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023245297-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023245297-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2023-12-28 | — | — | WO | disclosed |
| EP-2791121-B1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2791121-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8524745-B2 | Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2013090227-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150413-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| US-4185018-A | Process for producing benzofurazan-1-oxides | CIBA-GEIGY CORPORATION (US) | 1980-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | TDP1 828/4885TSHR 3098/4885MAPT 4531/4885 |
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | TDP1 1159/4885TSHR 4861/4885MAPT 1327/4885 |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | TDP1 3004/4885TSHR 4551/4885MAPT 4097/4885 |
| US-20130150413-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CCR5, CCR2, CX3CR1 | TDP1 4683/4885TSHR 676/4885MAPT 4339/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | TDP1 1123/4885TSHR 4861/4885MAPT 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.